{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:04:47Z","timestamp":1793127887582,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jtct.2022.04.008","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T16:03:49Z","timestamp":1649865829000},"page":"358-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moazzam","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernie","family":"Shippey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":false,"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-7987","authenticated-orcid":false,"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Divine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.04.008_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.04.008_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.04.008_bib0003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.04.008_bib0004","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma. March 8, 2021."},{"issue":"15_suppl","key":"10.1016\/j.jtct.2022.04.008_bib0005","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","article-title":"Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL)","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.04.008_bib0006","unstructured":"US Food and Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. July 27, 2020."},{"key":"10.1016\/j.jtct.2022.04.008_bib0007","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.04.008_bib0008","unstructured":"U.S. Food and Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. October 1, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.04.008_bib0010","unstructured":"US Food and Drug Administration. FDA approves new treatment for adults with relapsed or refractory large-B-cell lymphoma. February 5, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0011","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.04.008_bib0012","unstructured":"US Food and Drug Administration. FDA approves idecabtagene vicleucel for multiple myeloma. March 29, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0013","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.04.008_bib0014","unstructured":"US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, MD and Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies. January 15, 2019. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics. Accessed March 20, 2022."},{"key":"10.1016\/j.jtct.2022.04.008_bib0015","unstructured":"Novartis Pharmaceuticals Corporation. KYMRIAH risk evaluation and mitigation strategy (REMS). 2019 Available at: https:\/\/www.kymriah-rems.com\/. Accessed March 20, 2022"},{"key":"10.1016\/j.jtct.2022.04.008_bib0016","unstructured":"Kite Pharma, Inc. YESCARTA risk evaluation and mitigation strategy (REMS) program training. 2021 Available at: https:\/\/www.yescartatecartusrems.com\/. Accessed September 10, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-017-0239-0","article-title":"The why, what, and how of the new FACT standards for immune effector cells","volume":"5","author":"Maus","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2022.04.008_bib0018","unstructured":"Foundation for the Accreditation of Cellular Therapy (FACT). FACT accredited organizations for CART therapy administration 2021. Available at: https:\/\/accredited.factglobal.org\/. Accessed September 10, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0019","unstructured":"Kite Pharma, Inc. YESCARTA (axicabtagene ciloleucel) prescribing information 2022. Available at: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/oncology\/yescarta\/yescarta-pi.pdf. Accessed November 20, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0020","unstructured":"Novartis Pharmaceuticals Corporation. KYMRIAH (tisagenlecleucel) prescribing information 2021. Available at: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/kymriah.pdf. Accessed November 20, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0021","unstructured":"Mayo Clinic. CAR-T cell therapy program: frequently asked questions 2021. Available at: https:\/\/www.mayoclinic.org\/departments-centers\/car-t-cell-therapy-program\/sections\/gnc-20405547. Accessed September 20, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0022","unstructured":"Memorial Sloan Kettering Cancer Center. CAR T cell therapy: a guide for adult patients & caregivers 2021. Available at: https:\/\/www.mskcc.org\/cancer-care\/patient-education\/car-cell-therapy-guide-adult-patients-caregivers. Accessed September 20, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0023","unstructured":"BMTinfonet.org. Preparing for CAR T-cell therapy 2021. Available at: https:\/\/www.bmtinfonet.org\/transplant-article\/preparing-car-t-cell-therapy. Accessed September 20, 2021."},{"key":"10.1016\/j.jtct.2022.04.008_bib0024","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2022.04.008_bib0025","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1016\/j.vaccine.2017.10.083","article-title":"Determinants of influenza vaccination among high-risk Black and White adults","volume":"35","author":"Crouse Quinn","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jtct.2022.04.008_bib0026","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1055-9965.EPI-12-0466","article-title":"Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States","volume":"21","author":"Flowers","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtct.2022.04.008_bib0027","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.04.008_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.8161","article-title":"Enrollment of Black participants in pivotal clinical trials supporting US Food and Drug Administration approval of chimeric antigen receptor-T cell therapy for hematological malignant neoplasms","volume":"5","author":"Al Hadidi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtct.2022.04.008_bib0029","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1182\/bloodadvances.2021005148","article-title":"Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials","volume":"5","author":"Hantel","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.04.008_bib0030","doi-asserted-by":"crossref","first-page":"e16377","DOI":"10.2196\/16377","article-title":"Big data in context: addressing the twin perils of data absenteeism and chauvinism in the context of health disparities research","volume":"22","author":"Lee","year":"2020","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.jtct.2022.04.008_bib0031","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.008_bib0032","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s13187-014-0749-0","article-title":"Cancer research participation beliefs and behaviors of a southern Black population: a quantitative analysis of the role of structural factors in cancer research participation","volume":"30","author":"Farr","year":"2015","journal-title":"J Cancer Educ"},{"key":"10.1016\/j.jtct.2022.04.008_bib0033","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.2020008600","article-title":"When non-Whiteness becomes a condition","volume":"137","author":"Merz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.008_bib0034","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care-a health economics approach: an ISPOR special task force report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jtct.2022.04.008_bib0035","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtct.2022.04.008_bib0036","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamaoncol.2016.4865","article-title":"Out-of-pocket spending and financial burden among Medicare beneficiaries with cancer","volume":"3","author":"Narang","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2022.04.008_bib0037","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2022.04.008_bib0038","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1007\/s12325-021-01839-y","article-title":"Travel-related economic burden of chimeric antigen receptor T cell therapy administration by site of care","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.04.008_bib0039","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood-2021-146032","article-title":"Worsening financial toxicity among patients receiving chimeric antigen receptor T-cell (CAR-T) therapy: a mixed methods longitudinal study","volume":"138","author":"Cusatis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.04.008_bib0040","first-page":"1","article-title":"Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities","author":"Kansagra","year":"202040","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722012246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722012246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T23:47:33Z","timestamp":1726444053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722012246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2666636722012246"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.04.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}